US EditionLumos soars on US wins for FebriDx point-of-care respiratory test
Summary by Stockhead
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Lumos soars on US wins for FebriDx point-of-care respiratory test
Lumos secures reimbursement coverage for FebriDx with two Medicare Administration Contractors Reimbursement in Palmetto and Novitas regions is at US$41.38/test effective from start of April Negotiations continue with remaining five Medicare Administration Contractors Special Report: Lumos Diagnostics is up 18% today after significant milestones in its US reimbursement pathway for FebriDx test, a rapid point-of-care (POC) diagnostic designed to…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
